NASDAQ:ABOS Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis $0.20 -0.03 (-14.82%) As of 03:24 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Acumen Pharmaceuticals Stock (NASDAQ:ABOS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acumen Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.20▼$0.2250-Day Range$0.21▼$2.9252-Week Range$0.19▼$3.60Volume2.67 million shsAverage Volume1.19 million shsMarket Capitalization$14.18 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingReduce Company Overview Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease. Its research focuses on soluble amyloid beta oligomers, forms of the protein that the company believes contribute to the disease. The company’s lead investigational product, sabirnetug (ACU193), is a monoclonal antibody designed to selectively target amyloid beta oligomers. Acumen has evaluated the treatment in clinical studies of people with early Alzheimer’s disease; it is investigational and has not been approved for commercial use.AI Generated. May Contain Errors. Read More Acumen Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreABOS MarketRank™: 3.10861173965 of 5 starsAcumen Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 341st out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingReduce Consensus RatingAcumen Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.71, and is based on no strong buy ratings, 1 buy rating, 3 hold ratings, and 3 sell ratings.Upside PotentialAcumen Pharmaceuticals has a consensus price target of $1.00, representing about 410.2% upside from its current price of $0.20.Amount of Analyst CoverageAcumen Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Acumen Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Acumen Pharmaceuticals are expected to grow in the coming year, from ($1.50) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acumen Pharmaceuticals is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acumen Pharmaceuticals is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcumen Pharmaceuticals has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.02% of the float of Acumen Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcumen Pharmaceuticals has a short interest ratio ("days to cover") of 0.66, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acumen Pharmaceuticals has recently increased by 47.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcumen Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcumen Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.8 / 5News SentimentN/A News SentimentAcumen Pharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Healthcare companies.Search Interest6 people have searched for ABOS on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.20% of the stock of Acumen Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.01% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acumen Pharmaceuticals' insider trading history. Receive ABOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABOS Stock News HeadlinesAcumen Pharmaceuticals: 3 Key Takeaways for Long-Term InvestorsNovember 4, 2026 | fool.comBTIG Sticks to Their Buy Rating for Acumen Pharmaceuticals (ABOS)November 3, 2026 | theglobeandmail.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 18 at 1:00 AM | Weiss Ratings (Ad)Acumen Pharmaceuticals consensus price target decreased by 57.89% to $3.26November 3, 2026 | msn.comCantor Fitzgerald Downgrades Acumen Pharmaceuticals to Underweight From OverweightOctober 31, 2026 | marketscreener.comMAcumen plunges on mid-stage trial setback for Alzheimer’s candidateOctober 31, 2026 | seekingalpha.comAcumen Pharmaceuticals: Altitude-AD Failure Destroys The Investment Thesis (Rating Downgrade)October 31, 2026 | seekingalpha.comAcumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary EndpointOctober 30, 2026 | globenewswire.comSee More Headlines ABOS Stock Analysis - Frequently Asked Questions How have ABOS shares performed this year? Acumen Pharmaceuticals' stock was trading at $2.11 at the beginning of 2026. Since then, ABOS shares have decreased by 90.7% and is now trading at $0.1960. How were Acumen Pharmaceuticals' earnings last quarter? Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) posted its quarterly earnings data on Monday, October, 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.04. Read the conference call transcript. When did Acumen Pharmaceuticals IPO? Acumen Pharmaceuticals (ABOS) raised $150 million in an IPO on Tuesday, June 29th 2021. The company issued 9,999,999 shares at $14.00-$16.00 per share. Who are Acumen Pharmaceuticals' major shareholders? Acumen Pharmaceuticals' top institutional investors include State Street Corp (1.16%) and Empowered Funds LLC (0.12%). Insiders that own company stock include Daniel Joseph Oconnell, Matt Zuga, Eric Siemers, Russell Barton, Derek M Meisner, James J Doherty, Nathan B Fountain and Derrell Porter. View institutional ownership trends. How do I buy shares of Acumen Pharmaceuticals? Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acumen Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acumen Pharmaceuticals investors own include Palantir Technologies (PLTR), Caribou Biosciences (CRBU), Cabaletta Bio (CABA), Cognition Therapeutics (CGTX), Advanced Micro Devices (AMD), Annexon (ANNX) and Ardelyx (ARDX). Company Calendar Last Earnings10/26/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, ABOS's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABOS CIK1576885 Webwww.acumenpharm.com Phone434-297-1000FaxN/AEmployees61Year Founded1996Price Target and Rating Average Price Target for Acumen Pharmaceuticals$1.00 High Price Target$1.00 Low Price Target$1.00 Potential Upside/Downside+410.2%Consensus RatingReduce Rating Score (0-4)1.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$121.33 million Net MarginsN/A Pretax MarginN/A Return on Equity-166.49% Return on Assets-90.79% Debt Debt-to-Equity Ratio0.17 Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book0.41Miscellaneous Outstanding Shares72,330,000Free Float64,950,000Market Cap$14.18 million OptionableOptionable Beta0.51 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:ABOS) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.